Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03286062 · ClinicalTrials.gov registry record · Phase 1
VM110 in Detection of Microscopic Tumors: A Phase I Study
A Phase 1 study, sponsored by Fox Chase Cancer Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT03286062 is a Phase 1 study that was terminated before completion, run by Fox Chase Cancer Center. The registered enrollment target is 1 participants.
The verdict
NCT03286062, a Phase 1 study, was terminated before completion, sponsored by Fox Chase Cancer Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
A laproscopic imaging tecgnology that uses a synthetic agent to detect ovarian and pancreatic cancers at an early stage so that patients can get treatment early and prevent the disease from advancing to late stage leading to fatality or recurrence.
Interventions
- COMBINATION_PRODUCT Agent VM110 and laproscopic infra-red probe
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2017-10-12 |
| Est. Completion | 2020-04-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03286062
The ClinicalTrials.gov registry entry for NCT03286062 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fox Chase Cancer Center, which has 183 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Agent VM110 and laproscopic infra-red probe is the first listed.
NCT03286062 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03286062 about?
NCT03286062 is a clinical study titled "VM110 in Detection of Microscopic Tumors: A Phase I Study". A laproscopic imaging tecgnology that uses a synthetic agent to detect ovarian and pancreatic cancers at an early stage so that patients can get treatment early and prevent the disease from advancing to late stage leading to fatality or recurrence.
What is the current status of trial NCT03286062?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2017-10-12. Estimated completion is 2020-04-03.
What interventions are being tested in trial NCT03286062?
The interventions under investigation include: Agent VM110 and laproscopic infra-red probe (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT03286062?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.